Atezolizumab/bevacizumab and lenvatinib for HCC
Arndt Vogel shared the following post on X:
“Hot off the press – our European RWD study: Atezolizumab/bevacizumab and lenvatinib for HCC.
- Similar OS for Lenva vs AB
- Risk of hepatic decompensation for pts w/ impaired liver function under AB
- More data for clinical decision making.”
Nina Niu Sanford’s retweeted the post, adding her own thoughts:
“Worth noting median OS w atezo/bev here 13 mo vs. 19.2 mo in IMBRAVE150.
Biggest dif is prob 21% Child Pugh B here, but really highlights in HCC esp so many factors separate pts on trial vs. real world – underlying cirrhosis, dif biologies worldwide, PS, social supports, etc.”
Authors: de Castro, Tiago; Welland, Sabrina; Jochheim, Leonie; Leyh, Cathrine; Shmanko, Kateryna; Finkelmeier, Fabian; Jeliazkova, Petia; Jefremow, Andre; Gonzalez-Carmona, Maria A.; Kandulski, Arne; Roessler, Daniel; Ben Khaled, Najib; Enssle, Stefan; Venerito, Marino; Fründt, Thorben W.; Schultheiß, Michael; Djanani, Angela; Pangerl, Maria; Maieron, Andreas; Wirth, Thomas C.; Marquardt, Jens U.; Greil, Richard; Fricke, Christina; Günther, Rainer; Schmiderer, Andreas; Bettinger, Dominik; Wege, Henning; Scheiner, Bernhard; Müller, Martina; Strassburg, Christian P.; Siebler, Jürgen; Ehmer, Ursula; Waidmann, Oliver; Weinmann, Arndt; Pinter, Matthias; Lange, Christian M.; Saborowski, Anna; Vogel, Arndt
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
Dr. Nina Niu Sanford is an Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital. She specializes in treating gastrointestinal cancers and actively participates in clinical trials combining high-dose radiation therapy with immunotherapy. Additionally, she researches healthcare access disparities and conducts pan-cancer outcomes research using large databases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023